124 related articles for article (PubMed ID: 10533322)
21. Low-dose add-back therapy during postoperative GnRH agonist treatment.
Tsai HW; Wang PH; Huang BS; Twu NF; Yen MS; Chen YJ
Taiwan J Obstet Gynecol; 2016 Feb; 55(1):55-9. PubMed ID: 26927249
[TBL] [Abstract][Full Text] [Related]
22. Prevention of bone loss and hypoestrogenic symptoms by estrogen and interrupted progestogen add-back in long-term GnRH-agonist down-regulated patients with endometriosis and premenstrual syndrome.
Mitwally MF; Gotlieb L; Casper RF
Menopause; 2002; 9(4):236-41. PubMed ID: 12082359
[TBL] [Abstract][Full Text] [Related]
23. [Androgens and other hormones in buserelin therapy].
Fuchs U; Zwirner M
Geburtshilfe Frauenheilkd; 1991 Feb; 51(2):140-2. PubMed ID: 1904040
[TBL] [Abstract][Full Text] [Related]
24. [Clinical efficacy and safety of gonadotropin releasing hormone agonist combined with estrogen-dydrogesteronea in treatment of endometriosis].
Long QQ; Zhang SF; Han Y; Chen H; Li XL; Hua KQ; Hu WG
Zhonghua Fu Chan Ke Za Zhi; 2010 Apr; 45(4):247-51. PubMed ID: 20646533
[TBL] [Abstract][Full Text] [Related]
25. Reversible pituitary ovarian suppression induced by an LHRH agonist in the treatment of endometriosis--comparison of two dose regimens.
Shaw RW; Matta W
Clin Reprod Fertil; 1986 Oct; 4(5):329-36. PubMed ID: 3100012
[TBL] [Abstract][Full Text] [Related]
26. Gonadotropin-releasing hormone analogue (goserelin) plus hormone replacement therapy for the treatment of endometriosis: a randomized controlled trial.
Howell R; Edmonds DK; Dowsett M; Crook D; Lees B; Stevenson JC
Fertil Steril; 1995 Sep; 64(3):474-81. PubMed ID: 7641897
[TBL] [Abstract][Full Text] [Related]
27. Long-term effects on bone mineral density and bone metabolism of 6 months' treatment with gonadotropin-releasing hormone analogues in Japanese women: comparison of buserelin acetate with leuprolide acetate.
Makita K; Ishitani K; Ohta H; Horiguchi F; Nozawa S
J Bone Miner Metab; 2005; 23(5):389-94. PubMed ID: 16133689
[TBL] [Abstract][Full Text] [Related]
28. Treatment with a luteinising hormone-releasing hormone analogue (Buserelin) in danazol-resistant endometriosis patients.
Franssen AM; Rolland R; Chadha DR; Willemsen WN; Vemer HM
Eur J Obstet Gynecol Reprod Biol; 1986 Dec; 23(5-6):379-86. PubMed ID: 3100357
[TBL] [Abstract][Full Text] [Related]
29. Treatment of endometriosis with a decreasing dosage of a gonadotropin-releasing hormone agonist (nafarelin): a pilot study with low-dose agonist therapy ("draw-back" therapy).
Tahara M; Matsuoka T; Yokoi T; Tasaka K; Kurachi H; Murata Y
Fertil Steril; 2000 Apr; 73(4):799-804. PubMed ID: 10731543
[TBL] [Abstract][Full Text] [Related]
30. Changes in bone mineral content following hormone treatment for endometriosis.
Fukushima M
Int J Gynaecol Obstet; 1995 Sep; 50 Suppl 1():S17-22. PubMed ID: 8529770
[TBL] [Abstract][Full Text] [Related]
31. [Effects and safety of gonadotrophin-releasing hormone agonist combined with estradiol patch and oral medroxyprogesterone acetate on endometriosis].
Wang YQ; Zhang SF; Chen X; Zhu J; Hua KQ; Hu WG
Zhonghua Fu Chan Ke Za Zhi; 2009 Jul; 44(7):504-8. PubMed ID: 19957549
[TBL] [Abstract][Full Text] [Related]
32. [Hormonal changes in buserelin therapy].
Fuchs U; Zwirner M
Zentralbl Gynakol; 1989; 111(18):1236-40. PubMed ID: 2511705
[TBL] [Abstract][Full Text] [Related]
33. Effect of LH-RH agonist therapy in the treatment of endometriosis (German experience).
Cirkel U; Schweppe KW; Ochs H; Schneider HP
Prog Clin Biol Res; 1986; 225():189-99. PubMed ID: 3097665
[No Abstract] [Full Text] [Related]
34. Reversible trabecular bone density loss following induced hypo-oestrogenism with the GnRH analogue buserelin in premenopausal women.
Matta WH; Shaw RW; Hesp R; Evans R
Clin Endocrinol (Oxf); 1988 Jul; 29(1):45-51. PubMed ID: 3150319
[TBL] [Abstract][Full Text] [Related]
35. CA-125 monitored therapy with GnRH analogue of pelvic endometriosis.
Negri P; Ricciardelli MA; Tomasi A; Grechi E; Fortini RM
Acta Eur Fertil; 1992; 23(4):171-4. PubMed ID: 1343472
[TBL] [Abstract][Full Text] [Related]
36. The effect of LHRH agonist therapy in the treatment of endometriosis (Dutch experience).
Franssen AM; Kauer FM; Rolland R; Zijlstra JA; Willemsen WN; van 't Veen AJ
Prog Clin Biol Res; 1986; 225():201-10. PubMed ID: 3097666
[No Abstract] [Full Text] [Related]
37. Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding.
Lemay A; Faure N; Labrie F; Fazekas AT
Fertil Steril; 1985 Jun; 43(6):868-77. PubMed ID: 3158551
[TBL] [Abstract][Full Text] [Related]
38. Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis--a randomized, double-blind, multicenter, controlled trial.
Harada T; Momoeda M; Taketani Y; Aso T; Fukunaga M; Hagino H; Terakawa N
Fertil Steril; 2009 Mar; 91(3):675-81. PubMed ID: 18653184
[TBL] [Abstract][Full Text] [Related]
39. [Initial results in the treatment of endometriosis with the LH-RH analog buserelin].
Hardt W; Schmidt-Gollwitzer M; Schmidt-Gollwitzer K; Genz T; Nevinny-Stickel J
Geburtshilfe Frauenheilkd; 1986 Aug; 46(8):483-9. PubMed ID: 3093311
[TBL] [Abstract][Full Text] [Related]
40. Fourteen-day versus twenty-one-day regimens of intermittent intranasal luteinizing hormone-releasing hormone agonist combined with an oral progestogen as antiovulatory contraceptive approach.
Lemay A; Faure N
J Clin Endocrinol Metab; 1986 Dec; 63(6):1379-85. PubMed ID: 2946711
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
